RemeGen Receives $650 Million Upfront from AbbVie in Landmark $5.6 Billion Bispecific Antibody Licensing Deal

RemeGen Ltd (HKG: 9995) has announced the receipt of USD 650 million in upfront payment from AbbVie (NYSE: ABBV) under a strategic licensing agreement signed in January 2026. The deal grants AbbVie global rights to RC148, RemeGen’s novel PD-1/VEGF-targeting bispecific antibody (BsAb), with total potential consideration reaching USD 5.6 billion including up to USD 4.95 billion in development, regulatory, and commercial milestones.

Transaction Overview

Asset Profile – RC148

• Mechanism: First-in-class bispecific antibody simultaneously targeting PD-1 and VEGF pathways
• Therapeutic Rationale: Dual blockade addresses both immune evasion (PD-1) and angiogenesis (VEGF) in tumor microenvironment
• Development Stage: Advanced preclinical/early clinical development at time of deal
• Innovation Status: Represents next-generation immuno-oncology approach combining two validated but complementary mechanisms
• Competitive Position: Differentiated from combination therapies through single-molecule dual targeting

Scientific Advantages

• Synergistic Effect: Simultaneous PD-1 and VEGF inhibition may enhance anti-tumor efficacy compared to monotherapies or combinations
• Pharmacokinetic Optimization: Single bispecific molecule potentially offers improved dosing convenience and safety profile
• Tumor Microenvironment Modulation: Dual targeting addresses multiple resistance mechanisms in solid tumors

Strategic Rationale

For RemeGen Ltd

• Capital Infusion: USD 650 million upfront provides substantial non-dilutive funding for pipeline advancement
• Global Validation: Partnership with AbbVie validates RC148’s scientific and commercial potential
• Risk Mitigation: Transfers expensive late-stage development and commercialization costs to global partner
• Pipeline Acceleration: Enables parallel advancement of other proprietary assets including RC88 (mesothelin ADC) and RC118 (CLDN18.2 ADC)

For AbbVie Inc.

• Portfolio Diversification: Expands beyond TNF inhibitors into next-generation immuno-oncology
• Bispecific Leadership: Strengthens position in emerging bispecific antibody therapeutic class
• First-Mover Potential: Early access to innovative PD-1/VEGF dual targeting approach
• Commercial Synergies: Leverages existing oncology infrastructure and commercial capabilities

Market Context & Financial Impact

Bispecific Antibody Market

• Global Market Size: Bispecific antibodies projected to reach USD 25 billion by 2030
• PD-1/VEGF Combination: Emerging as promising approach in multiple solid tumor indications
• Deal Multiples: USD 5.6 billion total value reflects premium for innovative bispecific mechanisms
• China Biotech Valuation: Represents one of the largest outbound licensing deals from Chinese biotech sector

Financial Implications for RemeGen

• Cash Position: Significantly strengthened balance sheet supporting multi-year pipeline development
• Revenue Recognition: Upfront payment recognized immediately with milestones tied to development progress
• Shareholder Value: Substantial value realization without equity dilution
• Strategic Flexibility: Enhanced ability to pursue internal development and external partnerships

“This landmark deal with AbbVie represents a tremendous validation of our innovative bispecific antibody platform,” said Dr. Jianmin Gao, Founder, Chairman, and CEO of RemeGen. “RC148’s unique dual targeting of PD-1 and VEGF pathways has the potential to transform treatment paradigms across multiple solid tumor types, and AbbVie’s global expertise will accelerate its path to patients worldwide.”

Forward-Looking Statements
This brief contains forward-looking statements regarding partnership implementation, milestone achievements, and therapeutic potential. Actual results may differ due to risks including clinical trial outcomes, regulatory approvals, competitive developments, and uncertainties inherent in biopharmaceutical development.-Fineline Info & Tech